REAGENT or RESOURCE | SOURCE | IDENTIFIER |
---|---|---|
Antibodies | ||
Casirivimab | Laboratory of Hans-Martin Jäck | N/A |
Imdevimab | Laboratory of Hans-Martin Jäck | N/A |
Bamlanivimab | Laboratory of Hans-Martin Jäck | N/A |
Etesevimab | Laboratory of Hans-Martin Jäck | N/A |
hIgG | Laboratory of Hans-Martin Jäck | N/A |
Goat anti-Human IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 | Thermo Fisher Scientific | Cat# A-11013; RRID: AB_2534080 |
Goat anti-Human IgG (Fc)-HRPO | Dianova | Cat# 109-035-098; RRID: AB_2337586 |
Anti-VSV-G antibody (I1, produced from CRL-2700 mouse hybridoma cells) | ATCC | Cat# CRL-2700; RRID: CVCL_G654 |
Bacterial and virus strains | ||
VSV∗ΔG-FLuc | Laboratory of Gert Zimmer | N/A |
One Shot™ OmniMAX™ 2 T1R Chemically Competent E. coli | Thermo Fisher Scientific | Cat# C854003 |
Biological samples | ||
Convalescent plasma (ID15) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID18) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID20) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID22) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID23) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID24) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID27) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID33) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID51) | Laboratory of Martin S. Winkler | N/A |
Convalescent plasma (ID56) | Laboratory of Martin S. Winkler | N/A |
Vaccinee serum (L3) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L4) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L9) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L11) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L12) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L13) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L16) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L22) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L25) | Laboratory of Martin Lier | N/A |
Vaccinee serum (L26) | Laboratory of Martin Lier | N/A |
Vaccinee serum (ID6205) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6272) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6236) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6239) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6243) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6262) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6297) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6321) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6358) | Laboratory of Georg M. N. Behrens | N/A |
Vaccinee serum (ID6365) | Laboratory of Georg M. N. Behrens | N/A |
Chemicals, peptides, and recombinant proteins | ||
Soluble human ACE2 (sol-hACE2-Fc) | Laboratory of Stefan Pöhlmann | N/A |
Lipofectamine 2000 | Thermo Fisher Scientific | Cat# 11668019 |
Critical commercial assays | ||
Beetle-Juice Kit | PJK | Cat# 102511 |
Deposited data | ||
N/A | N/A | N/A |
Experimental models: cell lines | ||
293T | DSMZ | Cat# ACC-635; RRID: CVCL_0063 |
BHK-21 | Laboratory of Georg Herrler | ATCC Cat# CCL-10; RRID:CVCL_1915 |
Caco-2 | Laboratory of Stefan Pöhlmann | ATCC Cat# HTB-37; RRID: CVCL_0025 |
Calu-3 | Laboratory of Stephan Ludwig | ATCC Cat# HTB-55; RRID: CVCL_0609 |
Huh-7 | Laboratory of Thomas Pietschmann | JCRB Cat# JCRB0403; RRID: CVCL_0336 |
NCI-H1299 | Laboratory of Stefan Pöhlmann | ATCC Cat# CRL-5803; RRID:CVCL_0060 |
Vero76 | Laboratory of Andrea Maisner | ATCC Cat# CRL-1586; RRID: CVCL_0574 |
Experimental models: organisms/strains | ||
N/A | N/A | N/A |
Oligonucleotides | ||
Please see Table S3 | Sigma-Aldrich | N/A |
Recombinant DNA | ||
Plasmid: pCG1 | Laboratory of Roberto Cattaneo | N/A |
Plasmid: pCAGGS-VSV-G | Laboratory of Stefan Pöhlmann | N/A |
Plasmid: pCAGGS-DsRed | Laboratory of Stefan Pöhlmann | N/A |
Plasmid: pCG1-SARS-2-SΔ18 (B.1), codon-optimized | Laboratory of Stefan Pöhlmann | N/A |
Plasmid: pCG1-SARS-2-SΔ18 (B.1.351), codon-optimized | Laboratory of Stefan Pöhlmann | N/A |
Plasmid: pCG1-SARS-2-SΔ18 (B.1.621), codon-optimized | This study | N/A |
Plasmid: pCG1-SARS-2-SΔ18 (C.1.2 “early”), codon-optimized | This study | N/A |
Plasmid: pCG1-SARS-2-SΔ18 (C.1.2 “late”), codon-optimized | This study | N/A |
Plasmid: pCG1-solACE2-Fc | Laboratory of Stefan Pöhlmann | N/A |
Software and algorithms | ||
Hidex Sense Microplate Reader Software | Hidex Deutschland Vertrieb GmbH | https://www.hidex.de |
YASARA (version 19.1.27) | YASARA Biosciences GmbH | http://www.yasara.org |
SWISS-MODEL online tool | Protein Structure Bioinformatics Group, Swiss Institute of Bioinformatics Biozentrum, University of Basel |
https://swissmodel.expasy.org |
Adobe Photoshop CS5 Extended (version 12.0 x 32) | Adobe | https://www.adobe.com/ |
GraphPad Prism (version 8.3.0(538)) | GraphPad Software | https://www.graphpad.com/ |
FloJo (version 10.8) | Becton Dickinson | https://www.flowjo.com/ |
Flowing Software (version 2.5.1) | Turku Bioscience | https://bioscience.fi/services/cell-imaging/flowing-software/ |
Adobe Photoshop CS5 Extended (version 12.0 x 32) | Adobe | https://www.adobe.com/ |
Microsoft Office Standard 2010 (version 14.0.7232.5000) | Microsoft Corporation | https://products.office.com/ |
Other | ||
Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies (PDB: 6XDG) | (Hansen et al., 2020) | https://www.rcsb.org/structure/6XDG |
SARS-CoV 2 Spike Protein bound to LY-CoV555 (PDB: 7L3N) | (Jones et al., 2021) | https://www.rcsb.org/structure/7L3N |
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD (PDB: 7C01) | (Shi et al., 2020) | https://www.rcsb.org/structure/7C01 |
Distinct conformational states of SARS-CoV-2 spike protein (PDB: 6XR8) | (Cai et al., 2020) | https://www.rcsb.org/structure/6XR8 |